United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for BIOXYTRAN, INC? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | 96.87% | 63.47% | 38.41% | 27.78% | 21.85% | 18.32% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -532.61% | -597.03% | - | - | - | - |
| Total Assets | $658.55K | $148.64K | $148.64K | $148.64K | $148.64K | $148.64K |
| Net Income | -$2,123.08K | -$2,409.59K | -$2,377.64K | -$2,380.84K | -$2,394.13K | -$2,451.27K |